Anti-inflammatory and Antirheumatic Drugs
Authors: JOHN L. ABRUZZO
Journal: Annals of Internal Medicine (1981)

Editorial Notes1 February 1981Anti-inflammatory and Antirheumatic DrugsJOHN L. ABRUZZO, M.D.JOHN L. ABRUZZO, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-2-270 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMeclofenamate sodium (Meclomen; Parke-Davis, Morris Plains, New Jersey), a nonsteroidal anti-inflammatory agent of the fenamate group, has recently been approved by the U.S. Food and Drug Administration for clinical use in rheumatoid arthritis and osteoarthritis. Like the better known drugs in its class—indomethacin (Indocin; Merck Sharp & Dohme, West Point, Pennsylvania), ibuprofen (Motrin; The Upjohn Company, Kalamazoo, Michigan), tolmetin (Tolectin; McNEILAB, Inc., Ft. Washington, Pennsylvania), naproxen (Naprosyn; Syntex Laboratories, Inc., Palo Alto, California), sulindac (Clinoril; Merck & Company, Rahway, New Jersey), and fenoprofen calcium (Nalfon; Eli Lilly & Company, Indianapolis, Indiana)—meclofenamate sodium at its daily recommended dose (300 to 400...References1. DRESNER A. Multicenter studies with sodium meclofenamate (MeclomenR) in the United States and Canada. Curr Ther Res. 1978;23:S90-106. Google Scholar2. MYLES A, BACON P, and WILLIAMS K. Mefenamic acid in rheumatoid arthritis. Ann Rheum Dis. 1967;26:494-8. CrossrefMedlineGoogle Scholar3. PRESTON S. Safety of sodium meclofenamate (MeclomenR). Curr Ther Res. 1978;23:S107-12. Google Scholar4. . Testimony of PR VAGELOS , Merck Sharp & Dohme Research Laboratories, 15 April 1980. Google Scholar5. ZIZIC T, SUTTON J, and STEVENS M. Piroxicam and osteoarthritis: controlled study. Proc Roy Soc Med. 1978;1:71-2. Google Scholar6. PISKO E, RAHMAN M, TURNER R, and AGUDELO C. Long term efficacy and safety of piroxicam in the treatment of rheumatoid arthritis. Curr Ther Res. 1980;27:852-9. Google Scholar7. FINKELSTEIN A, ROISMAN F, and BATISTA V. Oral chrysotherapy in rheumatoid arthritis: minimum effective dose. J Rheumatol. 1980;7:160-8. MedlineGoogle Scholar8. SIMON T, KUNISHIMA D, VIBERT G, and LORBER A. Cellular anti-proliferative action exerted by auranofin. J Rheumatol. 1979;6:S91-7. Google Scholar9. WALZ D, DIMARTINO M, and GRISWOLD D. Immunopharmacology of auranofin and gold sodium thiomalate: Effects on humoral immunity. J Rheumatol. 1979;6:S74-81. Google Scholar10. WALZ D and GRISWOLD D. Immunopharmacology of gold sodium thiomalate and auranofin: effects on cell mediated immunity. Inflammation. 1978;3:117-28. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOHN L. ABRUZZO, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDoes DMSO affect the conformational changes of drug molecules in supercritical CO2 Media?Survey of antiinflammatory agents and related drugs as inhibitors of ovulation in the rabbitAnti-inflammatory analgesics and drugs used in rheumatoid arthritis and goutCorrection: Citation of Paper by DresnerARTHUR D. FLANAGAN, M.D. 1 February 1981Volume 94, Issue 2 Page: 270-271 Keywords Calcium Drugs Food and Drug Administration Ibuprofen NSAIDs Osteoarthritis Rheumatoid arthritis Sodium ePublished: 1 December 2008 Issue Published: 1 February 1981 PDF downloadLoading ...